Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Urticaria Pipeline Outlook
Key Takeaways from the Chronic Urticaria Pipeline Report
In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
DelveInsight's Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment.
The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others.
Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others.
Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs
Chronic Urticaria Emerging Drugs Profile
CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria.
Povorcitinib - Incyte Corporation
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.
Briquilimab: Jasper Therapeutics
Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.
The Chronic Urticaria Pipeline Report Provides Insights into-
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment.
Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market
Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight's detailed report now! @ New Chronic Urticaria Drugs
Chronic Urticaria Companies
Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others.
Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Chronic Urticaria Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers
Scope of the Chronic Urticaria Pipeline Report
Coverage- Global
Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others.
Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others.
Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Chronic Urticaria: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic Urticaria – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
Mid Stage Products (Phase II)
Povorcitinib - Incyte Corporation
Early Stage Products (Phase I)
Briquilimab: Jasper Therapeutics
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Chronic Urticaria Key Companies
Chronic Urticaria Key Products
Chronic Urticaria - Unmet Needs
Chronic Urticaria - Market Drivers and Barriers
Chronic Urticaria - Future Perspectives and Conclusion
Chronic Urticaria Analyst Views
Chronic Urticaria Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
11 hours ago
- CTV News
How to Get Rid of Strawberry Legs in Time for Summer
Say goodbye to strawberry legs with products from The Ordinary, First Aid Beauty, Drunk Elephant, and more. Let's talk strawberry legs, or those little bumps and dark spots on the skin that make you look kind of like a strawberry. Perhaps you've tried numerous products to rid your legs of the spots, or maybe you've attempted nothing at all, but are still on the hunt for that holy grail product. Whatever camp you fall into, you're in luck, because we've done our research to find you the best of the best. Each product is designed to either prevent strawberry legs or address the underlying causes, including clogged hair follicles, ingrown hairs, or folliculitis. Exfoliation works wonders To work the prevention angle, you'll want to focus on using products that keep your pores free of buildup. That means choosing the right exfoliating products. Chemical exfoliants, including alpha and beta-hydroxy acids, are great because they get the job done while also being gentle on the skin. The key is a good shave Shaving can do a number on your skin, especially if you don't have the right products. Opt for a gentle shaving cream with moisturizing agents, and always shave in the direction of hair growth. Ensuring that your razor is extra sharp and changed out frequently is also vital. This will reduce the risk of getting ingrown hairs that can make the appearance of strawberry legs worse. Skin nourishment matters Skipping the moisturizer would be like omitting the final touches on a work of art. You wouldn't leave a painting unfinished, and you won't skip the lotion on your legs after you've put in all the work with proper exfoliation and shaving. Choosing gentle, skin-barrier-loving moisturizers will keep your legs nourished, soft, and free of dryness that could make matters worse. Treating strawberry legs If your primary goal is treatment rather than prevention, there are a few products that can help with that, too. You just have to keep the same principles in mind, such as maintaining exfoliated skin and unclogged pores while minimizing the issues that can cause the strawberry leg look, including ingrown hairs. Product Testing: 5 Canadian Skincare Products I've Been Loving This Month This Canadian-Made Body Scrub And Oil Have Totally Changed My Summer Shaving Routine 15 Summer Beauty Must-Haves That Won't Break the Bank Disclaimer: The prices displayed are accurate at the time of publication. We'll do our best to keep them as up-to-date as possible, but you may see slight changes.
CTV News
15 hours ago
- CTV News
‘A very encouraging trend': Lethbridge sees drop in overdose deaths
The number of overdose deaths in Lethbridge appears to be declining. The city also no longer leads the province in highest overdose deaths per capita. The number of overdose deaths in Lethbridge appears to be declining. The city also no longer leads the province in highest overdose deaths per capita. In the first three months of 2025, Lethbridge only recorded two overdose deaths. That includes no deaths being recorded in March. Lethbridge peaked with 124 overdose deaths in 2023. But by 2024, the number was down to 42. If the current trend holds, Lethbridge would see its lowest number of overdose deaths since at least 2016. The province provided a statement on the drop in overdoses, saying, 'This is a very encouraging trend.' 'There have also been slight decreases in EMS responses and emergency department visits related to substance use in Lethbridge,' the province said. 'While we have made significant strides towards responding to the addiction crisis, more work continues to increase access to treatment and recovery from the disease of addiction.'
Globe and Mail
15 hours ago
- Globe and Mail
Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Chronic Urticaria Pipeline Insight, 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Urticaria Pipeline Outlook Key Takeaways from the Chronic Urticaria Pipeline Report In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable. DelveInsight's Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment. The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others. Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs Chronic Urticaria Emerging Drugs Profile CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria. Povorcitinib - Incyte Corporation Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria. Briquilimab: Jasper Therapeutics Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria. The Chronic Urticaria Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment. Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight's detailed report now! @ New Chronic Urticaria Drugs Chronic Urticaria Companies Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Chronic Urticaria Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers Scope of the Chronic Urticaria Pipeline Report Coverage- Global Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others. Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Chronic Urticaria: Overview Pipeline Therapeutics Therapeutic Assessment Chronic Urticaria – DelveInsight's Analytical Perspective Late Stage Products (Phase III) CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd Mid Stage Products (Phase II) Povorcitinib - Incyte Corporation Early Stage Products (Phase I) Briquilimab: Jasper Therapeutics Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Chronic Urticaria Key Companies Chronic Urticaria Key Products Chronic Urticaria - Unmet Needs Chronic Urticaria - Market Drivers and Barriers Chronic Urticaria - Future Perspectives and Conclusion Chronic Urticaria Analyst Views Chronic Urticaria Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
